Ursofalk

Ursofalk has a wide range of actions - it has a hepatoprotective, cholelitholytic, and immunomodulatory mechanism of action. Along with this, this drug contributes to a significant decrease in blood cholesterol.

Indications of the ursofalk

Drug medication Ursofalk is prescribed for the treatment of disorders of the gallbladder or liver, in which there is an increase in cholesterol, cholestasis, as well as violations in the liver, among which:

• reflux-gastritis, PBC liver and biliary reflux-esophagitis;
• cholangitis primary sclerosing;
• hepatitis of various origin (among them, disturbances in acute or chronic (accompanied by manifestations of cholestasis) forms, and also CAG - chronic inflammation of the liver, which is in a progressive stage);
• cholesterol concrements in the gallbladder (the drug should be taken only if their size in diameter is a maximum of 15 mm, the stones themselves are X-ray negative, and the patient has no disturbances in the gallbladder).

Indications for the use of drugs are also such diseases:

• Cystic fibrosis;
• Occurred as a result of acute or chronic alcohol poisoning, liver damage by toxins;
• Accompanying cholestasis disorders in the liver in a child, atresia of the bile ducts;
• Dysfunction of bile ducts;
• The drug can be used as a remedy for stagnation of bile arising from parenteral nutrition or after liver transplant surgery;
• Can be prescribed as a preventive measure when taking medications (eg, hormonal contraceptives or having a cholestatic effect) to prevent the risk of liver damage;
• As a prophylaxis of development of malignant neoplasms of the large intestine to people at risk.

[1], [2], [3]

Release form

Capsules - on a blister 10 pcs., In a pack 1 blister pack; on a blister of 25 pcs., in a pack of 2-4 blister plates.

Suspensions intended for oral administration are a 250 ml vial, in a pack of 1-2 vials. In addition, a measuring spoon is included.

Pharmacodynamics

The drug is used to protect liver function, and also has choleretic effect. Reduces the absorption of intestinal cholesterol, its synthesis in the liver, as well as its saturation in bile. Promotes the formation and removal of bile and increases the solubility of cholesterol. Reduces the lithogenicity of bile and at the same time increases the level of other bile acids in it. Activates lipase, increases the level of pancreatic and gastric juice, causes hypoglycemic effect. Enteral administration promotes complete or fragmentary dissolution of cholesterol stones and lowers the concentration of cholesterol in the bile, thereby stimulating its removal from the bile calculus. Due to the immunomodulating effect, the preparation has an effect on the immunological reactions in the liver: it reduces the expression of antigens in hepatocytes, influences the production of T-lymphocytes, and also the formation of IL-2. In addition, it reduces the number of eosinophils.

[4], [5]

Pharmacokinetics

Absorbed into the jejunum by passive transport; in the ileum - active transport. An intravenous dose of 500 mg after half an hour / 1 hour / 1.5 hours will reach such values of saturation in the blood serum, respectively: 3.8 / 5.5 / 3.7 μmol / liter. If you use UDCA regularly, it will become the predominant bile acid in the blood serum (amounting to 48% of their total number). It enters the system of enterohepatic circulation. The healing properties of Ursofalk are dependent on the level of concentration of UDC acid in bile. During treatment, the UDCA particle (according to the dosage) in the bile acid group increases to 50-75% (if the daily dosage is about 10-20 mg / kg). The substance can pass through the placenta.

[6], [7]

Dosing and administration

The reception is done orally, the capsule does not need to be chewed, only to drink with water. In case of a single use, it is recommended to use the medicine in the evening. For children or patients experiencing swallowing problems, the drug is administered in the form of a suspension.

Duration of therapy, as well as dosage, are appointed by the attending physician on an individual basis. They depend on the personal characteristics of the patient's body, as well as the nature of the disease.

When liver diseases (in acute or chronic form), including cholelithiasis, the drug is prescribed in a dosage of 10-15 mg / kg of weight per day. Treatment generally lasts at least six months, and a maximum of 2 years, discontinuation of the drug during this time is not recommended. In the treatment of cholelithiasis, you need to monitor the condition of the stones - if after 1 year of treatment there is no decrease, Ursofalk should be withdrawn.

With reflux esophagitis or biliary gall reflux gastritis, the dosage is 250 mg 1 r./day, best in the evening. The duration of therapy is 10-14 days.

With biliary cirrhosis or sclerosing cholangitis, the daily dosage is often 10-15 mg / kg body weight. If necessary, the dose may be increased to a value of 20 mg / kg body weight. The treatment course lasts from six months to two years.

With cystic fibrosis, the daily dosage is 20-30 mg / kg body weight. The therapeutic course continues also lasts a minimum of six months, a maximum of 2 years.

When alcohol poisoning (in acute or chronic form) or liver damage with toxins, the dosage is 10-15 mg / kg of body weight per day. The duration of the treatment course is made individually, but on average it lasts about six months or a year.

[10], [11], [12]

Use of the ursofalk during pregnancy

Absorbed into the jejunum by passive transport; in the ileum - active transport. An intravenous dose of 500 mg after half an hour / 1 hour / 1.5 hours will reach such values of saturation in the blood serum, respectively: 3.8 / 5.5 / 3.7 μmol / liter. If you use UDCA regularly, it will become the predominant bile acid in the blood serum (amounting to 48% of their total number). It enters the system of enterohepatic circulation. The healing properties of Ursofalk are dependent on the level of concentration of UDC acid in bile. During treatment, the UDCA particle (according to the dosage) in the bile acid group increases to 50-75% (if the daily dosage is about 10-20 mg / kg). The substance can pass through the placenta.

Contraindications

It is forbidden to take medicine if there is a high individual sensitivity to any of its elements.

Also it can not be prescribed to patients with cholangitis, acute cholecystitis, or blockage of the vesicle / bile duct. Contraindications for dysfunction of the gallbladder or biliary colic. Ursofalk is not allowed to be prescribed when the patient has calcified or confirmed by roentgenologic method biliary calculi.

[8]

Side effects of the ursofalk

Basically, the drug is transferred without side effects, but sometimes there may be a process of calcification of gallstones, pain in the epigastrium, or a mushy stool. Allergy may begin (hives, itching). In patients with PBC of the liver, a deterioration of well-being was observed, which came to normal after the withdrawal of the reception.

[9]

Overdose

At the moment there has been no report of an overdose.

[13], [14], [15], [16], [17], [18]

Interactions with other drugs

The combination of Ursofalk with antacid medicines, which contain aluminum hydroxide, and besides this with colestipol or colestyramine causes a decrease in the systemic absorption of UDCA. If a simultaneous appointment is necessary, the drugs should be consumed, making at least 2-hour intervals between the techniques.

In combination with cyclosporin it can change its concentration in plasma. Therefore, in the case of interaction with this drug, you need to carefully monitor the cyclosporine levels in the blood and adjust the dosage, if necessary.

[19], [20], [21], [22], [23], [24]

Storage conditions

The medicine should be kept in a completely dry place, closed from the penetration of direct sun rays. The air temperature should not exceed 25 ° C.

[25], [26], [27], [28], [29]

Shelf life

Ursofalk is allowed to be consumed within 5 years from the date of manufacture.

[30], [31], [32]